miR-345在非小细胞肺癌中的表达及临床意义

doi:10.11904/j.issn.1002-3070.2017.02.005

摘要/Abstract

摘要： 目的探讨microRNA-345(miR-345)在非小细胞肺癌(NSCLC)中的表达情况,并进一步分析其与肿瘤的临床病理特征和预后关系。方法利用Real-time PCR检测98例NSCLC患者组织及三种细胞系中miR-345的表达,分析miR-345的表达与临床预后的关系。结果和对照组相比,miR-345的表达在NSCLC组织及细胞系中显著下调(P＜0.05);组织中miR-345的表达水平和临床病理指标包括淋巴结转移(P＜0.001)、远端转移(P=0.028)、TNM分级(P=0.004)以及病理分期(P=0.011)有关;低表达miR-345的NSCLC患者组和高表达miR-345的患者组相比,其总生存率较低(P=0.021)。多因素分析表明miR-345的表达是NSCLC预后的独立危险因素(HR=3.897,95% CI:2.263~10.440;P=0.012)。结论 miR-345在NSCLC组织及细胞系中的表达降低,低表达的miR-345和NSCLC的进展及预后有关,表明miR-345可能作为NSCLC的一个潜在临床诊断标记。

关键词: 生物标记, miR-345, 非小细胞肺癌, 预后

Abstract: Objective The objective of this study was to investigate the miR-345 expression level in non-small cell lung cancer(NSCLC)tissue and its potential clinical significance.Methods Real-time PCR was conducted to evaluate the expression of miR-345 in NSCLC tissues in 98 samples and cell lines.Then the association between tissue miR-345 expression level and clinical outcomes was further analyzed.Results The expression level of miR-345 was significantly decreased in NSCLC tissues and cell lines when compared to the controls(P＜0.05).miR-345 expression level in NSCLS tissues was associated with various clinicopathological parameters including LN metastasis(P＜0.001),distant metastasis(P=0.028),TNM stage(P=0.004)and grade(P=0.011).In addition,the NSCLC patients in the low miR-345 expression group showed significantly shorter overall survival time than that in the high miR-345expression group(P=0.021).Multivariate analysis showed that the expression of miR-345 was an independent risk factor for NSCLC(HR=3.897,95% CI:2.263~10.440;P=0.012).Conclusion The expression level of miR-345 was decreased in NSCLC tissues as well as cell lines compared with normal controls.Low miR-345 expression in tissues was associated with progression and poor prognosis of NSCLC.These results indicate that miR-345 may be a novel prognostic marker in NSCLC.

Key words: Biomarker, miR-345, Non-small cell lung cancer, Prognosis

中图分类号:

R734.2

胡海峰, 冯谢敏, 乔健, 段伟, 刘宁宁, 孙晓东. miR-345在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2017, 31(2): 117-122.

HU Haifeng,FENG Xiemin,QIAO Jian,DUAN Wei,LIU Ningning,SUN Xiaodong. The expression and clinical significance of miR-345 in non-small cell lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 117-122.

参考文献

1 Siegel RL,Miller KD,Jemal A.Cancer statistics,2016[J].CA Cancer J Clin,2016,6(1):7-30.
2 Wink KC,Roelofs E,Solberg T,et al.Particle therapy for non-small cell lung tumors:where do we stand? A systematic review of the literature[J].Front Oncol,2014,4(32):292-296.
3 Blevins R,Bruno L,Carroll T,et al.MicroRNAs regulate cell-to-cell variability of endogenous target gene expression in developing mouse thymocytes[J].PLoS Genet,2015,11(2):e1005020.
4 Inamura K,Ishikawa Y.MicroRNA in lung cancer:novel biomarkers and potential tools for treatment[J].J Clin Med,2016,5(3):36-39.
5 高大登,李华栋,禹亮,等.MicroRNA与非小细胞肺癌关系的研究进展[J].现代生物医学研究进展,2013,13(14):2797-2800.
6 Nadal E,Truini A,Nakata A,et al.A novel serum 4-microRNA signature for lung cancer detection[J].Sci Rep,2015,5(1):12464-12468.
7 Mavridis K,Gueugnon F,Petit-Courty A,et al.The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients[J].Br J Cancer,2015,112(9):1527-1535.
8 Wang SY,Shiboski S,Belair CD,et al.MiR-19,miR-345,miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance[J].PLoS One,2014,9(6):e98597.
9 Kaur S,Lotsari JE,Al-Sohaily S,et al.Identification of subgroup-specific miRNA patterns by epigenetic profiling of sporadic and Lynch syndrome-associated colorectal and endometrial carcinoma[J].Clinical Epigenetics,2015,7(1):1-13.
10 Xue LM,Dong L,Yong ZM,et al.Overexpression of miR-708 and its targets in the childhood common precursor B-cell ALL[J].Pediatr Blood Cancer,2013,60(12):2060-2067.
11 Chen PS,Su JL,Hung MC.Dysregulation of microRNAs in cancer[J].Febs Letters,2012,19(1):1-8.
12 Ruan K,Fang X,Ouyang G.MicroRNAs:novel regulators in the hallmarks of human cancer[J].Cancer Lett,2009,285(2):116-126.
13 Pichler M,Calin GA.MicroRNAs in cancer:from developmental genes in worms to their clinical application in patients[J].Br J Cancer,2015,113(4):569-573.
14 Xue W,Dahlman JE,Tammela T,et al.Small RNA combination therapy for lung cancer[J].Proc Natl Acad Sci U S A,2014,111(34):3553-3561.
15 Sun Z,Yu JT,Jiang T,et al.Genome-wide microRNA profiling of rat hippocampus after status epilepticus induced by amygdala stimulation identifies modulators of neuronal apoptosis[J].PLoS One,2013,8(10):e78375.
16 Martinez-Ramos R,Garcia-Lozano JR,Lucena JM,et al.Differential expression pattern of microRNAs in CD4⁺ and CD19⁺ cells from asymptomatic patients with systemic lupus erythematosus[J].Lupus,2014,23(4):353-359.
17 Chen QG,Zhou W,Han T,et al.MiR-345 suppresses proliferation,migration and invasion by targeting Smad1 in human prostate cancer[J].J Cancer Res Clin Oncol,2016,142(1):213-224.
18 Srivastava SK,Bhardwaj A,Arora S,et al.MicroRNA-345 induces apoptosis in pancreatic cancer cells through potentiation of caspase-dependent and-independent pathways[J].Br J Cancer,2015,113(4):660-668.
19 Tang JT,Wang JL,Du W,et al.MicroRNA 345,a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer[J].Carcinogenesis,2011,32(8):1207-1215.
20 Schou JV,Rossi S,Jensen BV,et al.MiR-345 in metastatic colorectal cancer:a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan[J].PLoS One,2014,9(6):e99886.
21 Brito JA,Gomes CC,Guimaraes AL,et al.Relationship between microRNA expression levels and histopathological features of dysplasia in oral leukoplakia[J].J Oral Pathol Med,2014,43(3):211-216.
22 Gayosso-Gomez LV,Zarraga-Granados G,Paredes-Garcia P,et al.Identification of circulating miRNAs profiles that distinguish malignant pleural mesothelioma from lung adenocarcinoma[J].Excli J,2014,13(3):740-750.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[3]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[4]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[5]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[6]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[7]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.
[8]	张凤春, 江莺, 刘照南, 闫宁宁, 崔洪全, 徐迎春. 系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义[J]. 实用肿瘤学杂志, 2019, 33(1): 34-39.
[9]	马健力, 张明辉, 姬宏飞, 徐向英. PD-L1蛋白与CD8⁺TILs联合检测在可切除肺腺癌预后评估中的临床意义[J]. 实用肿瘤学杂志, 2019, 33(1): 40-46.
[10]	杨洪波, 石洁, 叶勇, 李文成, 邓兆平. COL5A2在膀胱癌组织中的表达及其与临床病理特征和预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 52-56.
[11]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[12]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[13]	肖洪伟, 陈升, 王艳良, 苏学良. 距肛缘≤8 cm的T₁期直肠癌患者经肛门局部切除术的预后及影响因素分析[J]. 实用肿瘤学杂志, 2018, 32(6): 545-549.
[14]	李万祯, 殷俊, 李萍, 林晓辉, 张国前, 张书旭. iR-17在非小细胞肺癌放射抗拒细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(5): 391-397.
[15]	王一然, 黄维, 尹蕾, 刘琳, 周晓平, 牛星鉴, 杨悦, 安巍巍, 姬宏飞. 中性粒细胞与淋巴细胞比值对宫颈癌患者同步放化疗疗效及预后判断的临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 404-409.